A study of M&A trends and effects on global pharmaceutical industry: using bayer schering pharma as a model

• Main Authors: Lin, Sandy, 林芮珊
• Other Authors: Wu, Jack
• Format: Others
• Language: en_US
• Published: 2009
• Online Access: http://ndltd.ncl.edu.tw/handle/73254250827257188729

碩士 === 國立政治大學 === 國際經營管理碩士班(IMBA) === 97 === Abstract A Study of M&A Trends and Effects on Global Pharmaceutical Industry: Using Bayer Schering Pharma as a Model By Sandy, Jui-San Lin The driving force for me to conduct a case writing related to M&A trends and effects in pharmaceutical industry as my master thesis is because I have been working with a global pharmaceutical subsidiary in Taipei whereby the company had experienced a series of post merger integrations. I was surprised by my research as 3 out of the 9 largest worldwide M&A transactions in 2000s were associated with pharmaceutics. The data is even more shocking as the total M&A value in pharmaceutical industry had contributed to almost 14% of the top transactions from 1990s to present (Table 1.2 & 1.3). I hope by going through the process, I will be able to learn more about the industry as what are the underlying factors and key considerations behind these mergers, how do those consolidated companies benefit from the action and where is the future? In my dissertation, I will first define what M&A action is as in general; present an overview on the global pharmaceutical world as what are the recent developments of M&A activities. Then I will concentrate on Bayer Healthcare and study its integration process with German Schering.